Aurinia Pharmaceuticals has entered a definitive merger agreement to acquire clinical-stage Kezar Life Sciences for $6.955 in cash per share. The all-cash deal delivers immediate value to Kezar shareholders; implications for Aurinia hinge on integration and how the acquisition affects its pipeline and capital allocation.
Aurinia Pharmaceuticals has entered a definitive merger agreement to acquire clinical-stage Kezar Life Sciences for $6.955 in cash per share. The all-cash deal delivers immediate value to Kezar shareholders; implications for Aurinia hinge on integration and how the acquisition affects its pipeline and capital allocation.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
